Enhancing Antibody Drug Conjugates Efficacy in Glioblastoma through Overcoming Blood-Brain Barrier Challenges
Time: 8:30 am
day: Workshop B (New)
Details:
Due to the restrictive nature of the blood-brain barrier, there are many difficulties in drug delivery to the GBM. While ADCs offer targeted therapy by linking monoclonal antibodies with cytotoxic agents, their effectiveness in GBM is hindered by the BBB’s physical and biochemical barriers. This workshop will provide an in-depth examination of the strategies to improve ADC delivery and efficacy in GBM, focusing on overcoming BBB limitations and optimizing therapeutic outcomes.
Key Discussion Points:
- BBB Disruption and ADC Penetration: Analyze methods to enhance ADC delivery across the BBB, including chemical-induced disruption techniques and their potential for improving ADC efficacy in GBM treatment
- Current Success & Applicability in Pre-Clinical & Clinical Trials: Reviewing the current landscape for ADCs in treating glioblastoma alongside other CNS tumors
- Internalization and Cellular Mechanisms: Exploring challenges related to ADC internalization and lysosomal degradation, such as defects in cellular trafficking and lysosomal function, and reviewing approaches to enhance ADC cellular uptake and payload release
